Previous 10 | Next 10 |
Deciphera Pharmaceuticals (NASDAQ: DCPH ): Q1 GAAP EPS of -$1.36 misses by $0.05 . More news on: Deciphera Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
- NDA for Ripretinib for the Treatment of Advanced GIST Under Review by U.S. FDA with PDUFA Date of August 13, 2020; Commercial Preparations Underway to Support Potential Launch - - COVID-19 Business Update Provided; Clinical and Commercial Milestone Timing Affirmed - - First Qua...
Shares of Blueprint Medicines (NASDAQ: BPMC) fell nearly 21% today after the company announced that its lead drug candidate, avapritinib, failed an important late-stage study in gastrointestinal stromal tumors (GIST). The experimental therapy didn't lead to an improvement in progression-free...
Broadwind Energy (NASDAQ: BWEN ) +60% . on $19M order . More news on: Broadwind Energy, Inc., TrovaGene, Inc., SmileDirectClub, Inc., Stocks on the move, , Read more ...
Deciphera Pharmaceuticals (NASDAQ: DCPH ) is up 16% premarket on light volume on the heels on Blueprint Medicines' plunge after announcing unsuccessful results from late-stage study of avapritinib in gastrointestinal stromal tumor (GIST) patients. More news on: Deciphera...
Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, today announced that it will report its first quarter 2020 financial results on Tuesday, May 5, 2020. In connection with the earnings re...
There are plenty of intriguing biotech stocks on the market right now, and many of them are trading at a steep discount due to the coronavirus pandemic. However, no matter how exciting a company's prospects might be, investors still need to do their due diligence before choosing to invest in any...
Shares of Deciphera Pharmaceuticals ( DCPH ) have risen by 20% since my August 2019 update called the stock a Buy based on ripretinib's impressive showing in fourth-line and fourth-line plus gastrointestinal stromal tumors (GIST). Targeted oncology has been one of my favored themes to capita...
Shares of Deciphera Pharmaceuticals (NASDAQ: DCPH) fell nearly 23% last month, according to data from S&P Global Market Intelligence . Investors are concerned that the company's long-awaited transition to commercial operations will be delayed by the coronavirus pandemic. It's not a...
Deciphera Pharmaceuticals, Inc. (DCPH) Q4 2019 Earnings Conference Call March 09, 2020, 04:30 PM ET Company Participants Jennifer Robinson - VP, IR Steven Hoerter - President and CEO Matthew Sherman - Chief Medical Officer Daniel Martin - Chief Commercial Officer Tucker Kelly...
News, Short Squeeze, Breakout and More Instantly...
Deciphera Pharmaceuticals Inc. Company Name:
DCPH Stock Symbol:
NASDAQ Market:
Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced that members of the management team will participate in a fireside chat at the St...
2024-03-21 19:56:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-03-11 17:52:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...